Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials

Yangxun Pan(Sun Yat-sen University), Zhongguo Zhou(Sun Yat-sen University), Yaojun Zhang(Sun Yat-sen University), Ruojing Wang(Sun Yat-sen University), Wa Xie(Sun Yat-sen University), Jiajie Hou(University of Macau), Li Xu(Fujian Medical University), Dandan Hu(Tongji University), Minshan Chen(Sun Yat-sen University), Yizhen Fu(Sun Yat-sen University)
Frontiers in Bioscience-Landmark
October 29, 2021
10.52586/4994
Cited by 19

Related Papers

Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216
Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis
|Journal of Clinical Investigation|2018|190